Mallinckrodt will acquire Questcor to create a diversified, high-growth specialty pharmaceuticals company.
Mallinckrodt and Questcor Pharmaceuticals have entered into an agreement under which Mallinckrodt will acquire Questcor for approximately $5.6 billion. Subject to customary closing conditions, the transaction is currently expected to be completed in the third quarter of 2014.
“With Questcor, combined with our recently completed acquisition of Cadence Pharmaceuticals, the new Mallinckrodt will have an increasingly diversified specialty pharmaceuticals portfolio, which will include novel therapeutics for pain management, as well as central nervous system, renal, rheumatologic, and other autoimmune and inflammatory disorders," said Mark Trudeau, president and CEO of Mallinckrodt, in a press release.
Questcor's H.P. Acthar Gel (repository corticotropin injection) is expected to be a strong complement to Mallinckrodt's portfolio of specialty pharmaceutical brands. Acthar generated net sales for Questcor of $761.3 million in 2013. Acthar is an injectable drug approved by FDA for the treatment of 19 indications, many of which are associated with the treatment of autoimmune and inflammatory conditions.
Trudeau will lead the combined company, which is expected to increase its board of directors to twelve members with the addition of three directors from Questcor. Melvin D. Booth, the current chairman of Mallinckrodt's Board of Directors, will continue in that role after the transaction is completed. Upon closing, Questcor commercial operations will function as a separate business unit within Mallinckrodt's Specialty Pharmaceuticals segment reporting directly to Trudeau. Mallinckrodt expects to add Questcor executives to Mallinckrodt's leadership team; these individual appointments will be announced at a later date. Mallinckrodt will continue to be domiciled in Ireland with its main executive office in Dublin.
Source: Mallinckrodt
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.